Additional File 1

Benefit of switching to mepolizumab from omalizumab in severe eosinophilic asthma based on patient characteristics

Mark C Liu, Bradley Chipps, Xavier Munoz, Gilles Devouassoux, Miguel Bergna,

Steven G Smith, Robert G Price, Dmitry V Galkin, Jay Azmi, Dalal Mouneimne, Frank C

Albers, Kenneth R Chapman

List of figures

Additional Figure S1. Efficacy of switching to mepolizumab from omalizumab by baseline ACQ-5 or SGRQ score quartiles.

ACQ quartiles: <2.5 (n=35)   2.5–<3.0 (n=20)   3.0–<3.5 (n=37)   ≥3.5 (n=53)
SGRQ quartiles: <45 (n=40)   45–<55 (n=31)   55–<70 (n=40)   ≥70 (n=34)

*Pre-treatment refers to the 12 months prior to screening; †32-week study period refers to the time between first dose of mepolizumab and study conclusion, regardless of treatment discontinuation. Rate ratio reflecting annualised clinically significant exacerbation rate during 32-week study period compared with rate during pre-treatment period. MCID for ACQ-5 and SGRQ is 0.5 points and 4 points, respectively; error bars represent SE.

ACQ, Asthma Control Questionnaire; CI, confidence interval; FEV$_1$, Forced expiratory volume in 1 second; LS, least squares; MCID, minimum clinically important difference; RR, rate ratio; SE, standard error; SGRQ, St George's Respiratory Questionnaire.

Additional Figure S2. Efficacy of switching to mepolizumab from omalizumab by baseline body weight or BMI quartiles.


Weight (kg) quartiles: <70 (n=32) 70–<80 (n=32) 80–<95 (n=46) ≥95 (n=35)
BMI (kg/m²) quartiles: <25 (n=31) 25–<30 (n=47) 30–<35 (n=38) ≥35 (n=29)

*Pre-treatment refers to the 12 months prior to screening; †32-week study period refers to the time between first dose of mepolizumab and study conclusion, regardless of treatment discontinuation. Rate ratio reflecting annualised clinically significant exacerbation rate during 32-week study period compared with rate during pre-treatment period. MCID for ACQ-5 and SGRQ is 0.5 points and 4 points, respectively; error bars represent SE.

ACQ, Asthma Control Questionnaire; BMI, body mass index; CI, confidence interval; FEV_1, Forced expiratory volume in 1s; LS, least squares; MCID, minimum clinically important difference; RR, rate ratio; SE, standard error; SGRQ, St George's Respiratory Questionnaire.